I. Introduction

II. Major Product Development Opportunities

A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products

III. Design Criteria for Decentralized Testing Products

IV. Alternative Market Penetration Strategies

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets

V. Potential Market Entry Barriers and Risks

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. Overview of Major Tests,

Technologies and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Carbapenemase
13. Chagas Disease
14. Chancroid
15. Chlamydia
16. Clostridium Difficile
17. Coronaviruses
18. Coxsackieviruses
19. Creutzfeldt-Jakob's Disease
20. Cryptosporidium Parvum
21. Cyclospora Cayetanensis
22. Cytomegalovirus
23. Ebola Virus
24. E. Coli
25. Echovirus
26. Encephalitis
27. Enteroviruses
28. Epstein-Barr Virus
30. Giardia Lamblia
31. Gonorrhea
32. Granuloma Inguinale
33. Hantavirus
34. Helicobacter Pylori
35. Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
36. Herpes Simplex Virus
37. Human Herpes Virus-6 (HHV-6)
38. Influenza Viruses
39. Legionella
40. Lyme Disease
41. Lymphogranuloma Venereum (LGV)
42. Malaria
43. Measles (Rubeola)
44. Meningitis
45. Microsporidium
46. Mononucleosis
47. Mumps
48. Mycoplasma
49. Norovirus
50. Papillomaviruses
51. Parvovirus B19
52. Pneumonia
53. Polyomaviruses
54. Pseudomonas Aeruginosa
55. Rabies
56. Respiratory Syncytial Virus (RSV)
57. Rhinoviruses
58. Rotavirus
59. Rubella
60. Salmonellosis
61. Septicemia
62. Shigellosis
63. Staphylococcus Aureus
64. Streptococci
65. Syphilis
66. Toxoplasmosis
67. Trichomonas Vaginalis
68. Tuberculosis
69. Vibrio
70. West Nile Virus
71. Yersina
B. Instrumentation Review: Operating Characteristics,
Features and Selling Princes of Leading Infectious Disease
Automated and Semi-automated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing

VII. Country Analyses: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares

- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- UK

VIII. Competitive Assessments

- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- Hologic/Gen-Probe
- ID Biomedical/GSK
- Kreatech/Leica
- Lonza
- Ortho-Clinical Diagnostics
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens
- Takara Bio
- Thermo Fisher
- Wallac/PE
- Wako